<DOC>
	<DOCNO>NCT01363674</DOCNO>
	<brief_summary>This National , Multicentre , Observational Registry study adherence long term outcome therapy paediatric subject use Easypod™ electromechanical device growth hormone treatment hospital Greece ass level adherence subject receive SAIZEN® via Easypod™ .</brief_summary>
	<brief_title>To Assess Level Adherence Subjects Receiving SAIZEN® Via Easypod™ Greece</brief_title>
	<detailed_description>Subjects enrol multicenter , longitudinal observational registry . Parents/subjects provide Informed Consent/assent upload data populationbased analysis optionally adhere patient adherence support program design improve adherence , ultimately , clinical outcome . Adherence data primarily derive Easypod™ device combine physician data entry outcome measure . Data collect retrospectively prospectively . This allow establishment adherence profile explore hypothesis patient adherence support program improve adherence subsequent clinical outcome . Collected data also analyze multinational pooled analysis comparable national study . Primary Objective : - To assess level adherence subject receive SAIZEN® via Easypod™ Secondary Objectives : - To identify adherence subject profile - To describe impact adherence clinical outcome subject receive SAIZEN® via Easypod™ - To asses impact adherence Insulin-like Growth Factor 1 ( IGF1 ) ( i.e . , within normal range ) - To assess/describe impact Greek Scientific Service ( Patient Support Program )</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Administered growth hormone ( SAIZEN® ) via Easypod™ autoinjector , accord approve Summary Product Characteristics ( SmPC ) Naïve subject already treat SAIZEN® Easypod™ 1 year Male female 2 18 year age , 18 without fusion growth plat Parent 's guardian 's ( subject 's 18 without fusion growth plat ) write informed consent , give enter data registry , understand subject parent/guardian may withdraw consent time without prejudice future medical care . Subjects take growth hormone growth plate fuse ( i.e . take growth hormone metabolic effect ) Contraindications SAIZEN® define approve SmPC Use investigational drug participation another interventional clinical study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Growth disorder</keyword>
	<keyword>Saizen</keyword>
	<keyword>Easypod</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Pediatric subject</keyword>
</DOC>